CHENNAI, India – August 1, 2025 — Morulaa announced that Sophysa, a global leader in neurosurgical innovation, has received CDSCO approval through the Import License process (CDSCO Form MD-15) from the Central Drugs Standard Control Organization, part of the Ministry of Health and Family Welfare of India. The approval covers its SOPHY® adjustable cranial drainage valves and preattached drainage kits, now officially registered under the India medical device registration framework.
SOPHY® Devices in Hydrocephalus Care: Neurosurgical Applications in India
Hydrocephalus affects millions globally and remains a major indication for shunting and drainage procedures. Sophysa’s adjustable valves and external kits are trusted by neurosurgeons, neurocritical care physicians, and pediatric specialists across the globe. The systems are designed to be MRI-compatible and offer fine control over CSF flow.
Regulatory Highlights Under MDR 2017
Morulaa HealthTech Pvt. Ltd., a specialist CDSCO consultant in India, facilitated Sophysa’s medical device market entry into India. Morulaa supports global companies with CDSCO import licenses, Indian distributor onboarding, and ongoing compliance under India’s Medical Device Rules, 2017 (MDR 2017). Their expertise enables manufacturers from Europe and the USA to navigate the complex regulatory landscape and secure timely approvals.
This specific CDSCO import license covers the Cranial drainage devices and Cranial drainage preattached kits.
The SM8 and SM1‑L valves provide neurosurgeons and neurocritical care physicians with precision control in CSF drainage. Combined with disposable and sterile kit configurations, they support safe and effective hydrocephalus management in both adult and pediatric neurosurgical contexts.
The approved Class B–C neurosurgical devices are indicated for the treatment of hydrocephalus, a condition caused by excess cerebrospinal fluid (CSF) in the brain. The devices enable safe diversion of CSF to relieve intracranial pressure and are used in both adult and pediatric neurosurgical procedures. Now it meets CDSCO’s stringent medical device registration requirements in India, allowing authorized Indian CDSCO agents to facilitate distribution.
“SOPHY® devices are designed to deliver consistent, safe, and precise fluid regulation to support better patient outcomes.”
With this CDSCO approval, Sophysa’s cranial drainage portfolio — including adjustable valves (SOPHY® SM8, SM1‑L), external drainage kits, reservoirs, and catheter accessories — is now eligible for sale and distribution through certified Indian distributors, completing the final step in CDSCO agent-led market access strategy.
About Sophysa
Sophysa is an international medical device company founded in 1976, recognized for developing the first adjustable valve for hydrocephalus. Its product range includes CSF shunting systems, intracranial pressure monitoring, external drainage, and subcutaneous access ports. Visit www.sophysa.com for more information.
About Morulaa: CDSCO Consultants & Market Entry Experts in India
Morulaa HealthTech is a regulatory and CDSCO consulting firm based in India, supporting medical device registration for India across all classes. From preparing a robust Device Master File (DMF) to managing CDSCO Form MD-14/MD-15 submissions, Morulaa ensures timely approvals. The company also supports medical device market entry in India through strategic distributor onboarding, registration file compilation, and representation as a CDSCO agent.
Morulaa has enabled multiple manufacturers from the USA and Europe to achieve fast-track compliance for India’s regulatory ecosystem. Visit www.morulaa.com for full-service information on CDSCO import license assistance, predicate device alignment, and authorized agent services.
Follow us on Facebook, LinkedIn, and Twitter or visit Morulaa.
Forward-looking Statements
This document contains forward-looking statements regarding plans, expectations, and future events. Forward-looking statements involve risks and uncertainties that could cause actual outcomes to differ. Statements are based on current information as of this release date and are not guarantees of future performance.